Essex Savings Bank Purchases 192 Shares of AstraZeneca PLC (NASDAQ:AZN)

Essex Savings Bank lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,772 shares of the company’s stock after acquiring an additional 192 shares during the period. Essex Savings Bank’s holdings in AstraZeneca were worth $424,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in AZN. Banque Transatlantique SA acquired a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $26,000. Confluence Investment Management LLC bought a new position in shares of AstraZeneca in the 1st quarter valued at $27,000. Mascagni Wealth Management Inc. acquired a new stake in shares of AstraZeneca during the 4th quarter valued at $29,000. FNY Investment Advisers LLC acquired a new position in AstraZeneca in the 1st quarter worth about $29,000. Finally, Highline Wealth Partners LLC raised its position in AstraZeneca by 447.4% in the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock valued at $31,000 after purchasing an additional 340 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.3%

Shares of NASDAQ:AZN opened at $70.76 on Thursday. The business has a fifty day simple moving average of $70.15 and a 200 day simple moving average of $70.36. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The firm has a market cap of $219.45 billion, a P/E ratio of 28.42, a P/E/G ratio of 1.30 and a beta of 0.38. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same period last year, the company earned $2.06 earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. Analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, BNP Paribas began coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.